| Factor Information | |
|---|---|
| Data ID | 2809 |
| Factor | Diuretics, mg/kg/day |
| Description | When patients on continuous venovenous hemofiltration were compared with patients not on continuous venovenous hemofiltration, diuretic administration was lower (1.5 vs. 10 mg/kg/day), extracorporeal membrane oxygenation duration was longer (7 [range, 6-14]) vs. 4 [range, 3-8] days), and survival decreased from 60% (four of seven) to 33% (one of three). |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | diagnosis and prognosis |
| Objective | To evaluate diagnostic and prognostic significance of neutrophil gelatinase-associated lipocalin during extracorporeal membrane oxygenation in children with congenital heart disease. |
| p Value | 0.0002 |
| Conclusion | When patients on continuous venovenous hemofiltration were compared with patients not on continuous venovenous hemofiltration, diuretic administration was lower (1.5 vs. 10 mg/kg/day), extracorporeal membrane oxygenation duration was longer (7 [range, 6-14]) vs. 4 [range, 3-8] days), and survival decreased from 60% (four of seven) to 33% (one of three). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 626 |
| CHD Type | isolated CHD |
| CHD Subtype | AVC/TA/TOF/HLHS/MS/AC, VSD/UVH, HAA |
| Reference | |
|---|---|
| PMID | 21057360 |
| Year | 2012 |
| Title | Neutrophil gelatinase-associated lipocalin levels during extracorporeal membrane oxygenation in critically ill children with congenital heart disease: preliminary experience |
| Sample | ||
|---|---|---|
| Population | infants, children | |
| Source | Database | |
| Region | Rome, Italy | |
| Method | Prospective observational study. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Patients on CVVH (CVVH=continuous venovenous hemofiltration)(Treatment) | Patients Not on CVVH(Control) |
| Number | 3 | 7 |
| Age | 31 (7–5008) days | 13 (9–3056) days |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 1.5 (0.5–3) mg/kg/day | 10 (5–12) mg/kg/day |
